主页 > 生命科学 >

【drug-news】Roche cancer pill as effective as intravenous

口服药物能达到静注药物的药动学特性,令人振奋!

http://today.reuters.com/news/articlebusiness.aspx?type=health&storyID=nL02913271&imageid=&cap=&from=business

LONDON, Oct 2 (Reuters) - An oral chemotherapy regimen using Roche's (ROG.VX: Quote, Profile, Research) cancer pill Xeloda is as effective -- in terms of progression-free survival -- as standard intravenous treatment in patients with advanced colorectal cancer.

Results from a Phase III trial presented on Monday at the European Society for Medical Oncology Congress in Istanbul showed the easy-to-take XELOX regimen worked as well as traditional FOLFOX-4 treatment, researcher said.

The study also demonstrated that adding the targeted cancer drug Avastin, developed by Roche and its partner Genentech (DNA.N: Quote, Profile, Research), improved the chances of delaying progression of disease by 20 percent.

"Based on the results, XELOX may offer a new treatment option for metastatic (advanced) colorectal cancer that is as effective as the current standard treatment," Professor Jim Cassidy of Glasgow University, co-lead investigator for the study, said.

Because XELOX includes Xeloda, which is given by mouth, patients on this regimen spend less time in hospital. They receive a two-hour infusion in hospital followed by taking tablets at home, instead of a continuous 48-hour infusion on FOLFOX-4.

The researchers added that no new safety issues related to Xeloda or Avastin were observed in the trial, involving hundreds of patients with colorectal cancer that had spread to other parts of their body.

About Xeloda

Xeloda is licensed in more than 90 countries worldwide including the EU, USA, Japan, Australia and Canada and has been shown to be effective, safe, simple and convenient oral chemotherapy treating over 1 million patients to date.

Roche received marketing authorisation for Xeloda as a first-line monotherapy (by itself) in the treatment of metastatic colorectal cancer (colorectal cancer that has spread to other parts of the body) in most countries (including the EU and USA) in 2001. Xeloda has also been approved by the European Medicines Agency (EMEA) and U.S. Food and Drug Administration (FDA) for adjuvant (post-surgery) treatment of colon cancer in March and June 2005, respectively.

Xeloda is licensed in combination with Taxotere (docetaxel) in women with metastatic breast cancer (breast cancer that has spread to other parts of the body) and whose disease has progressed following intravenous (i.v.) chemotherapy with anthracyclines. Xeloda monotherapy is also indicated for treatment of patients with metastatic breast cancer that is resistant to other chemotherapy drugs such as paclitaxel and anthracyclines. Xeloda is licensed for the first-line treatment of stomach cancer that has spread, in South Korea.

The most commonly reported adverse events with Xeloda include diarrhoea, abdominal pain, nausea, stomatitis and hand-foot syndrome. 在过去几十年里,5-FU一直是胃肠道肿瘤联合化疗的基石。希罗达作为氟嘧啶前体的口服化疗药物,具有模拟5-FU持续静脉注射的药动学特性,近年受到国内外肿瘤界的高度重视。从今年ASCO公布的这些临床试验结果来看,希罗达是一个安全有效的、能够与其他药物联合应用的理想药物,对老年患者同样耐受性良好。希罗达的适应证也在不断扩大。希罗达二联及三联方案对晚期胃癌显示了非常好的疗效及安全性,目前韩国已经批准其用于晚期胃癌的治疗。

以下是关于希罗达联合其他药物使用的疗效报告
http://www.rocheoncology.com.cn/news/b_view.asp?ID=664 LONDON, Oct 2 (Reuters) - An oral chemotherapy regimen using Roche's (ROG.VX: Quote, Profile, Research) cancer pill Xeloda is as effective -- in terms of progression-free survival -- as standard intravenous treatment in patients with advanced colorectal cancer.
伦敦,10.02(路透社)--一种使用罗士公司(ROCHE)生产的口服抗肿瘤药希罗达(Xeloda)的化疗方案在晚期结直肠癌病人无肿瘤进展生存率上被证明与标准静脉疗法同样有效。
Results from a Phase III trial presented on Monday at the European Society for Medical Oncology Congress in Istanbul showed the easy-to-take XELOX regimen worked as well as traditional FOLFOX-4 treatment, researcher said.
研究者称,在伊斯坦布尔由欧洲医学肿瘤学协会于周一发布的一项III期临床试验表明:易于实施的XELOX方案与传统的FOLFOX-4方案同样有效。
The study also demonstrated that adding the targeted cancer drug Avastin, developed by Roche and its partner Genentech (DNA.N: Quote, Profile, Research), improved the chances of delaying progression of disease by 20 percent.

阅读本文的人还阅读:

¡¾Arteriosclerosis, Thrombo

【drug-news】PNAS:线粒体

论著:罗格列酮对心肌梗

【THORAC. CARDIOVASC. SURG.编

【medical-news】病例讨论:

作者:admin@医学,生命科学    2011-01-16 05:14
医学,生命科学网